NCT06113302View on ClinicalTrials.gov

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

June 2, 2026

Study Completion Date

June 2, 2026

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Luspatercept

Given by SC or (Injection)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT06113302 - A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter